(This Feb. 10 story has been refiled to say 'LOEs (loss of exclusivity),' not 'LOEs (levels of evidence),' in paragraph 13) ...

Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

NEW YORK/FRANKFURT (Reuters) - Merck KGaA, the German healthcare and technology group, said on Monday it is in advanced talks to acquire U.S. cancer and rare diseases drugmaker SpringWorks ...

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the introduction of a Caregiver Leave Benefit as an addition ...

Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare ...

Stamford-based SpringWorks Therapeutics, a commercial-stage biotech company developing treatments for rare diseases and ...

SpringWorks Therapeutics stock surged over Monday after a report from Reuters that German medical tech giant Merck KGaA could be close to acquiring the company.

NEW YORK/FRANKFURT (Reuters) - Merck KGaA, the German healthcare and technology group, said on Monday it is in advanced talks to acquire U.S. cancer and rare diseases drugmaker SpringWorks ...

After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.